Source Fact: Financial Supervisory Service DART / 2024-03-11
Disclosure Type: Turnover or Corporate Profit/Loss Structure Change of 30% or More (15% for Large Corporations)
💡 3-Second Summary
Driven by increased milestone inflows and technical service fees from its ALT-B4 platform, Alteogen’s consolidated revenue for the fiscal year skyrocketed by 235% year-on-year to KRW 96.5B, while narrowing its operating loss significantly to KRW 9.7B.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Company Name: Alteogen Co., Ltd. (Ticker: 196170)
- Financial Statement Type: Consolidated Financial Statements (Based on K-IFRS, Pre-audit Preliminary Figures)
- Details of Profit/Loss Structure Variance (Unit: KRW):
- Revenue: 96,522,928,887 (Increased by 67,716,584,389 compared to 28,806,344,498 in the prior fiscal year, +235.0%)
- Operating Income: -9,736,838,487 (Deficit continued, but loss decreased by 19,636,841,791 compared to -29,373,680,278 in the prior year; deficit compressed by 66.8%)
- Profit Before Income Tax from Continuing Operations: -3,564,374,999 (Deficit compressed by 64.2%)
- Net Income: -3,582,208,686 (Deficit continued, but loss decreased by 6,495,695,430 compared to -10,077,904,116 in the prior year; deficit compressed by 64.4%)
- Consolidated Financial Position (Unit: KRW):
- Total Assets: 256,099,994,583 / Total Liabilities: 108,258,260,247 / Total Equity: 147,841,734,336 / Capital Stock: 26,505,914,000
- Primary Reasons for Financial Performance Changes:
- Revenue Expansion: Growth in technical service revenue from the 2nd CMO setup of ALT-B4 licensing client companies and expansion of cumulative ALT-B4 milestone receipts.
- Operating Income Variance: Higher R&D expenses invested into active ALT-B4 advancements and CMC (Chemistry, Manufacturing, and Controls) developments for ALT-L9.
- Net Income Variance: A reduction in valuation gains on financial instruments measured in accordance with K-IFRS guidelines.
- Separate/Non-consolidated Financial Performance Data:
- Secured separate revenue of KRW 83.48B (up 854.0% year-on-year), a separate operating loss of KRW 0.9B (loss decreased by 95.7%), and a separate net profit of KRW 4.87B (up 130.3%), achieving a turnaround into profitability on a non-consolidated basis.
📈 2. [Expert View: What This Disclosure Means for Investors]
This regulatory filing presents preliminary unaudited financial statistics indicating significant year-on-year earnings fluctuations before the formal closing. While the exact line items remain subject to minor modifications during the final external audit process and annual shareholders’ review, the metrics confirm that commercial platform execution is translating into top-line numbers, signifying a positive mid-to-long-term development in the company’s operational fundamental.
The critical takeaway from this text is the substantial top-line expansion and the distinct financial stabilization on a separate basis. Driven by technical services and step-by-step milestone allocations from its ALT-B4 out-licensing partners, consolidated revenue scaled up to KRW 96.5B. Although the consolidated group printed an operating loss of KRW 9.7B due to continuous R&D outlays from consolidated subsidiaries, the parent firm generated a separate net profit of KRW 4.87B on separate revenue of KRW 83.48B, demonstrating improved underlying profitability. Because R&D investments and adjustments in financial asset valuations remain ongoing variables, a balanced strategy requires market participants to verify the upcoming formal audit reports and monitor the precise timeline for consolidated net profitability under a long-term horizon.
📝 Editor’s Comment (by K-STOCK Editor)
Alteogen has successfully demonstrated the commercial value of its out-licensing platforms through its preliminary financial sheets. The structural highlight of this filing is that the exponential revenue growth is anchored in verified operational drivers—namely, active milestone collections and CMO technical service fees linked to its ALT-B4 partners. While a consolidated net loss of KRW 3.5B means a full group-level deficit exit is still pending due to subsidiary R&D commitments, the deficit itself was compressed to roughly one-third of the prior year’s figure. More importantly, the parent entity achieved a sharp turnaround on a separate basis, printing KRW 83.48B in revenue and KRW 4.87B in net profit. Since these figures are pre-audit estimates, keeping an eye out for the upcoming formal audit report remains essential, but the reduction in fiscal cash-drain risks establishes a stable financial floor to support upcoming international clinical milestones.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on the official data submitted to the Electronic Disclosure System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
